Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2017 pubmed 17 citations

The antimicrobial peptide derived from insulin-like growth factor-binding protein 5, AMP-IBP5, regulates keratinocyte functions through Mas-related gene X receptors.

Chieosilapatham. Panjit P; Niyonsaba. François F; Kiatsurayanon. Chanisa C; Okumura. Ko K; Ikeda. Shigaku S; Ogawa. Hideoki H

Key Findings

  • AMP-IBP5 sharply increased keratinocyte migration and proliferation in vitro.
  • The peptide selectively raised levels of the cytokine IL‑8 and the growth factor VEGF, with VEGF rise linked to higher intracellular cAMP.
  • Its effects were blocked by silencing MrgX1‑X4 receptors or inhibiting MAPK/NF‑κB pathways, confirming those as the signaling routes.

Practical Outcomes

  • If a safe, skin‑compatible formulation can be made, AMP-IBP5 might be used as a topical agent to accelerate wound healing or improve skin repair, which could interest biohackers focused on skin health and anti‑aging. However, because the data are limited to cell culture, optimal dosing, safety, and real‑world effectiveness remain unknown and need further study.

Summary

Researchers found that a new peptide called AMP-IBP5, which is similar to the well‑known antimicrobial peptide LL‑37, can make skin cells (keratinocytes) grow and move faster, and it boosts two important healing signals (IL‑8 and VEGF). It works through specific skin receptors (MrgX1‑X4) and activates common cell‑growth pathways (MAPK and NF‑κB). This suggests the peptide could help speed up wound healing, but the work was done only in cell dishes, not in people.

Abstract

In addition to their microbicidal properties, host defense peptides (HDPs) display various immunomodulatory functions, including keratinocyte production of cytokines/chemokines, proliferation, migration and wound healing. Recently, a novel HDP named AMP-IBP5 (antimicrobial peptide derived from insulin-like growth factor-binding protein 5) was shown to exhibit antimicrobial activity against numerous pathogens, even at concentrations comparable to those of human β-defensins and LL-37. However, the immunomodulatory role of AMP-IBP5 in cutaneous tissue remains unknown. To investigate whether AMP-IBP5 triggers keratinocyte activation and to clarify its mechanism. Production of cytokines/chemokines and growth factors was determined by appropriate ELISA kits. Cell migration was assessed by in vitro wound closure assay, whereas cell proliferation was analyzed using BrdU incorporation assay complimented with XTT assay. MAPK and NF-κB activation was determined by Western blotting. Intracellular cAMP levels were assessed using cAMP enzyme immunoassay kit. Among various cytokines/chemokines and growth factors tested, AMP-IBP5 selectively increased the production of IL-8 and VEGF. Moreover, AMP-IBP5 markedly enhanced keratinocyte migration and proliferation. AMP-IBP5-induced keratinocyte activation was mediated by Mrg X1-X4 receptors with MAPK and NF-κB pathways working downstream, as evidenced by the inhibitory effects of MrgX1-X4 siRNAs and ERK-, JNK-, p38- and NF-κB-specific inhibitors. We confirmed that AMP-IBP5 indeed induced MAPK and NF-κB activation. Furthermore, AMP-IBP5-induced VEGF but not IL-8 production correlated with an increase in intracellular cAMP. Our findings suggest that in addition to its antimicrobial function, AMP-IBP5 might contribute to wound healing process through activation of keratinocytes.

Study Information

Provider

pubmed

Year

2017

Date

2017-05-16T00:00:00.000Z

DOI

10.1016/j.jdermsci.2017.05.008

Citations

17

References

41